COVID-19 clinical trial: UB launches monoclonal antibody study for household members of anyone who recently tested positive

Asymptomatic individuals are eligible to receive the drug within 96 hours of exposure

Release Date: November 10, 2020

Print
headshot of Sanjay Sethi in lab.
“At a time when our region is unfortunately experiencing an uptick in cases, we are pleased that we are able to provide Western New Yorkers with the opportunity to enroll in a study of this very promising potential COVID-19 treatment. ”
Sanjay Sethi, MD, Chief, Division of Pulmonary, Critical Care and Sleep Medicine
Jacobs School of Medicine and Biomedical Sciences

BUFFALO, N.Y. — Western New Yorkers who were recently exposed to a household member who has tested positive for COVID-19 now have an opportunity to be treated with a promising drug being investigated for COVID-19 infection.  

Researchers at the University at Buffalo are currently recruiting household members of individuals who have tested positive for COVID-19 to enroll in the UB study of Regeneron’s national clinical trial of the investigational antibody cocktail REGN-COV2. The drug has been shown to block infectivity of the novel coronavirus.

“At a time when our region is unfortunately experiencing an uptick in cases, we are pleased that we are able to provide Western New Yorkers with the opportunity to enroll in a study of this very promising potential COVID-19 treatment,” said Sanjay Sethi, MD, principal investigator on the study and chief of the Division of Pulmonary, Critical Care and Sleep Medicine in the Jacobs School of Medicine and Biomedical Sciences at UB. Sethi is also medical director of UB’s Clinical Research Office and a physician with UBMD Internal Medicine.

The monoclonal antibody treatment is believed to reduce the severity of symptoms in individuals exposed to COVID-19 or possibly even prevent symptoms entirely.

“If, for example, I test positive, then any member of my household could be eligible for this treatment provided that they haven’t begun experiencing symptoms,” said Sethi.

Safe clinic site was made available

The availability of a discrete site where individuals exposed to the novel coronavirus could be safely treated without exposing other patients was an important factor in being able to host this study in Western New York.

Sethi explained that the study was able to go forward thanks to the efforts of Jacobs School Dean Michael Cain in making available for the research a medical school clinic on Maple Road in Amherst that isn’t currently in use.

“We are very grateful to the dean that this clinic that isn’t currently in use was made available to us so that we could proceed with this critical study,” said Sethi.

At the site, potential participants will receive a rapid test for COVID-19. They will be able to participate whether or not they test positive. Individuals who are symptomatic will not be eligible for this study but could consider participating in treatment trials being conducted at UB for mild to moderate COVID-19.   

Participants will receive a single subcutaneous (under the skin) injection of either the treatment or a placebo. Because the study is double-blind, neither the participant nor the health care personnel administering the injection will know what the injection consists of.

Unlike antibodies contained in convalescent plasma of people who have recovered from COVID-19, this antibody drug is manufactured in the laboratory, and has been designed to bind to the spike protein of the coronavirus, thus possibly blocking the virus’ ability to invade cells and multiply.

Interested individuals who were recently exposed to COVID-19 from a household member and are interested in participating should contact Kelly Green at 716-888-4764 or by email at kjk22@buffalo.edu for more information.

Media Contact Information

Ellen Goldbaum
News Content Manager
Medicine
Tel: 716-645-4605
goldbaum@buffalo.edu
Twitter: @UBmednews